J 2016

Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role?

KREJČÍ, Jan; Petr HUDE; Eva OZABALOVA; Dalibor MLEJNEK; Víta ŽAMPACHOVÁ et. al.

Basic information

Original name

Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role?

Authors

KREJČÍ, Jan (203 Czech Republic, guarantor, belonging to the institution); Petr HUDE (203 Czech Republic); Eva OZABALOVA (203 Czech Republic); Dalibor MLEJNEK (203 Czech Republic, belonging to the institution); Víta ŽAMPACHOVÁ (203 Czech Republic, belonging to the institution); Iva SVOBODOVÁ (203 Czech Republic, belonging to the institution); Radka STEPANOVA (203 Czech Republic) and Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution)

Edition

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Palacký University, 2016, 1213-8118

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Czech Republic

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 0.894

RIV identification code

RIV/00216224:14110/16:00090789

Organization unit

Faculty of Medicine

UT WoS

000392810500011

EID Scopus

2-s2.0-85006309706

Keywords in English

inflammatory cardiomyopathy; endomyocardial biopsy; echocardiography; NTproBNP; right heart catheterization

Tags

Tags

International impact, Reviewed
Changed: 1/3/2017 09:11, Ing. Mgr. Věra Pospíšilíková

Abstract

In the original language

Aims. To compare the differences between patients with inflammatory cardiomyopathy (ICM) with and without improvement in left ventricular (LV) systolic function and to identify the relevant predictors of LV improvement. Patients and Methods. The study included 63 patients with biopsy-proven ICM and heart failure symptoms of at least NYHA II, symptom duration <= 6 months, LV ejection fraction (LVEF) <= 40% assessed by echocardiography and presence of >14 mononuclear leukocytes (LCA+ cells)/mm2 in biopsy samples. Patients were evaluated at baseline and after 6 months. Results. In the group with LVEF improvement of >= 10% (I+ group, n = 41), LVEF increased from 24 ± 7% to 47 ± 8% (P < 0.001). In 22 patients (group I-), there was no or minimal LVEF increase (< 10%). In the I+ group, there were more LCA+ cells/mm2 at baseline (25.1 ± 16.5 vs. 18.5 ± 4.4 cells/mm2; P = 0.032) and a more significant decrease in LCA+ cells in the follow-up (reduction of 13.6 ± 14.3 cells/mm2 vs. 5.0 ± 7.7 cells/mm2 in the I- group; P = 0.009). The univariate logistic regression showed a possible association of number of LCA+ cells, LV end-diastolic diameter and N-terminal fragment of pro-brain natriuretic peptide (NTproBNP) value with LVEF improvement. In the multivariate analysis, only NTproBNP at diagnosis was confirmed as an independent predictor of LVEF improvement (OR=1.2; 1.003 to 1.394; P = 0.046). Conclusion. The LV systolic function improvement was observed in 65% of the patients. In these patients, the number of inflammatory cells at baseline was higher and decreased more but the higher baseline NTproBNP value was the only independent predictor of LVEF improvement.

Links

MUNI/A/1270/2015, interní kód MU
Name: Význam bioptické diagnostiky u nově vzniklé dilatační kardiomyopatie
Investor: Masaryk University, Category A